Final results from ASPECCT: Randomized phase 3 non-inferiority study of panitumumab (pmab) vs cetuximab (cmab) in chemorefractory wild-type (WT) <i>KRAS</i> exon 2 metastatic colorectal cancer (mCRC).

Price, Timothy; Peeters, Marc; Kim, Tae Won; Li, Jin; Cascinu, Stefano; Ruff, Paul; Suresh, A.; Thomas, Anne; Tjulandin, Sergei; Zhang, Kathy; Sidhu, Roger; Murugappan, Swaminathan

doi:10.1200/jco.2015.33.15_suppl.3586

Cited by 3 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Grade ≥3 infusion reactions occurred less frequently with panitumumab (<0.5%) than cetuximab (2%). Final results have confirmed the non-inferiority of panitumumab to cetuximab for OS in chemotherapyresistant wild-type KRAS (exon 2) mCRC (31).…”

Section: Introductionmentioning

confidence: 60%

RAS and BRAF in metastatic colorectal cancer management

Gong

Cho

Fakih

2016

J. Gastrointest. Oncol.

View full text Add to dashboard Cite

The treatment of metastatic colorectal cancer (mCRC) has been further refined with the development of monoclonal antibodies, cetuximab and panitumumab, towards the epidermal growth factor receptor (EGFR). Anti-EGFR therapy has afforded improved survival in those with wild-type RAS mCRC but provides no benefit and even harm in those with RAS-mutant tumors. mutations have also been shown to predict lack of clinically meaningful benefit to anti-EGFR therapy in mCRC. Mechanisms of resistance to EGFR blockade in wild-type or metastatic colorectal tumors appear to converge on the mitogen-activated protein kinase (MAPK) signaling pathway. Clinical trials involving combined BRAF, EGFR, and/or MAPK kinase (MEK) inhibition have shown promising activity in-mutant mCRC. Here, we review pivotal clinical trials that have redefined our treatment approach in mCRC with respect to anti-EGFR therapy based on and mutation status. Future studies will likely focus on improving efficacy of anti-EGFR-based therapy in mCRC through sustained MAPK pathway inhibition.

show abstract

Section: Introductionmentioning

confidence: 60%

RAS and BRAF in metastatic colorectal cancer management

Gong

Cho

Fakih

2016

J. Gastrointest. Oncol.

View full text Add to dashboard Cite

show abstract

“…In fact, progressive improvement and stabilization of the skin eruption over weeks are usually observed [2,4]. However, 10% of patients may experience a more severe reaction [5] that may become refractory to the use of tetracyclines as inour case [1,2]. In these cases, isotretinoin should be considered an effective and safe alternative to be used, as it permits continuation of the antineoplastic treatment, a key point for cancer patients [3,6].…”

Section: Severe Acneiform Eruption Secondary To Cetuximab Successfully Treated With Isotretinoin Case Presentationmentioning

confidence: 99%

Severe Acneiform Eruption Secondary to Cetuximab Successfully Treated with Isotretinoin

Montes‐Torres¹,

Camarero-Mulas²

2021

Mathews Journal of Dermatology

View full text Add to dashboard Cite

“…Although anecdotal evidence has suggested that panitumumab-associated skin reactions often occur more frequently than those attributable to cetuximab, investigators have found that the incidence of AEs of any grade and grade 3/4 AEs were similar between cetuximab- and panitumumab-treated patients with mCRC in the randomized, third-line, monotherapy ASPECCT study, the only head-to-head trial comparing panitumumab and cetuximab. Of particular interest in ASPECCT, 13% of patients treated with panitumumab and 10% of those treated with cetuximab developed grade 3/4 skin reactions [21, 22]. Furthermore, cetuximab-associated [23] and panitumumab-associated [24] skin reactions generally start within the first 3 weeks of initiating treatment for mCRC.…”

Section: Introductionmentioning

confidence: 99%